Trust is Earned

over 300,000 Patients Treated

20 Years of Experience

Literature Summary
Long Term Experiences with the GORE® EXCLUDER® AAA Endoprosthesis.


**Objectives**
The objective of this study was to report the 10-year outcomes of the multicenter Italian Excluder Registry for elective endovascular aneurysm repair (EVAR).

**Summary of Results**

<table>
<thead>
<tr>
<th>461 PATIENTS, 10 YEARS FOLLOW UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>63% Cumulative survival</td>
</tr>
<tr>
<td>88% Estimated freedom from EG-related complication</td>
</tr>
<tr>
<td>81% Freedom from reintervention</td>
</tr>
</tbody>
</table>

Cumulative freedom from endoleak rate was significantly different between the two different follow-up intervals (0 to 5 year, 2.6% vs. 6 to 10 year, 0.8%, *P* < .001).

**Summarized Conclusion**
The Italian Excluder Registry outcomes confirmed sustained EVAR effectiveness at 10-year follow-up using the Gore Excluder EG. Freedom from EG-related complications, endoleaks, and reinterventions was satisfactory and remained acceptable beyond 5 years of follow-up, supporting a reasonable long-term durability of this device.

2. Long-Term Outcome of the GORE EXCLUDER AAA Endoprosthesis for Treatment of Infrarenal Aortic Aneurysms *Journal of Vascular and Interventional Radiology* 2017;S1051-0443(17)30153-7.

**Objectives**
To evaluate long-term outcome of GORE EXCLUDER AAA Endoprosthesis for elective treatment of infrarenal aortic aneurysms and to evaluate performance of different generations of the device.

**Summary of Results**

<table>
<thead>
<tr>
<th>248 PATIENTS, UP TO 10 YEARS FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>76% reintervention-free survival</td>
</tr>
<tr>
<td>97% Technical success</td>
</tr>
<tr>
<td>49% Overall survival survival with no aneurysm-related deaths</td>
</tr>
<tr>
<td>0.4% limb occlusion, rupture, migrations</td>
</tr>
</tbody>
</table>

**Summarized Conclusion**
Treatment with the GORE EXCLUDER is effective with acceptable reintervention rates in the long-term and few device-related adverse events or ruptures up to 10 years.

**Objectives**
To present short and mid-term outcomes from 200 consecutive patients treated prospectively with the C3 Gore Excluder stent-graft in a single institution.

**Summary of Results**

<table>
<thead>
<tr>
<th>200 PATIENTS, MEAN FOLLOW UP OF 17.8 MONTHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>98% Technical success, no failures associated with stent-graft malfunction</td>
</tr>
<tr>
<td>0% Mortality at 30 days for elective cases</td>
</tr>
<tr>
<td>0% Limb occlusion, Type I or III Endoleaks, Migrations</td>
</tr>
<tr>
<td>95% of the patients had a sac shrinkage or a stable sac diameter</td>
</tr>
</tbody>
</table>

**Summarized Conclusion**
The GORE® EXCLUDER® AAA Endoprosthesis showed excellent early and mid-term outcomes with no mortality, low reintervention rates and favorable sac remodeling.


**Objectives**
The aim of this study was to assess the effectiveness of EVAR, specifically assessing the durability of EVAR utilizing the Gore® EXCLUDER® AAA Endoprosthesis by analyzing the long-term performance.

**Summary of Results**

<table>
<thead>
<tr>
<th>144 PATIENTS WITH LONGEST FOLLOW UP OF 67.6 MONTHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>15% of patients treated were female</td>
</tr>
<tr>
<td>0% Type I or III Endoleaks</td>
</tr>
<tr>
<td>0% Migrations</td>
</tr>
<tr>
<td>0% Limb occlusions (1 patient)</td>
</tr>
<tr>
<td>0.8% Rupture post-implant</td>
</tr>
</tbody>
</table>

**Summarized Conclusion**
Long-term data associated with the GORE® EXCLUDER® AAA Endoprosthesis is relevant because of the consistent device design throughout the duration of the study. As evidenced by high patency, low reinterventions and consistent rupture prevention, EXCLUDER® can be offered as a durable solution for EVAR treatment.
ITalian Excluder Registry Investigators.


**Objectives**

To report the midterm results of elective EVAR of abdominal aortic aneurysms. It is the largest clinical unsponsored registry using a single device, with the longest follow-up period so far.

**Summary of Results**

**872 PATIENTS UP TO 5 YEARS FOLLOW UP**

- **97.9%** Estimated freedom from AAA-related death
- **86.5%** Freedom from all reintervention
- **Only 1** reported Type III endoleak
- **1.1%** Limb Thrombosis
- **0.5%** Migrations

**Summarized Conclusion**

The present experience confirms the near-term effectiveness of EVAR using the GORE® EXCLUDER® Device with low mortality rate, as well as the high rate of technical success and the low rate of endograft-related complication.


**Objectives**

This study was designed to assess the long-term outcome of selected patients with aortic, aortoiliac, and isolated common iliac aneurysms treated with the GORE EXCLUDER® stent-graft.

**Summary of Results**

**121 PATIENTS WITH MEAN FOLLOW-UP OF 4.98 YEARS**

- **66%** Aortic aneurysm
- **21%** Aortoiliac aneurysm
- **13%** Isolated common iliac aneurysm
- **0%** Late Aneurysm Rupture
- **0%** Early or late Type III endoleaks identified

**Summarized Conclusion**

GORE® EXCLUDER® AAA Endoprosthesis Demonstrated DURABILITY over a long-term follow-up period with NO aneurysm rupture or Type III endoleaks.
References


These articles may include descriptions of outcomes that reflect use of devices outside the approved Instructions for Use. Gore does not promote off-label uses of its devices. Physicians should consult the IFU for complete device information, including contraindications, warnings and cautions.

Additional literature references available upon request.

To receive access to reprints or full text version of these papers, please refer to a Gore Associate.

Products listed may not be available in all markets.

GORE®, C3®, EXCLUDER®, and designs are trademarks of W. L. Gore & Associates.

© 2017 W. L. Gore & Associates GmbH  AW3117-EN1  SEPTEMBER 2017